Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36715772

about

The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides.Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.Expression of the GLP-1 receptor in mouse, rat, and human pancreas Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.New therapeutic approaches in type 2 diabetes.The diabetic cardiomyopathy.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Liraglutide: clinical pharmacology and considerations for therapy.Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.Diabesity: an overview of a rising epidemic.The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

P2860

Q28538567-DFE2617B-6468-476D-891D-5BAD6D627B5D Q34381400-6EEC72DD-DDAF-4A17-81E5-8F550EBF99FE Q34407868-DC878C87-5BFC-4C48-A182-A911DEDA7644 Q35688754-B714DFD6-DDA4-4E0A-8C4A-621FE7125DDB Q36073461-67D61EF1-709F-484C-BA14-EF827C74D46A Q36363950-736D303B-DA5D-481C-8227-9641C380BAFE Q36715125-CB2137CC-9BBA-4115-B5F8-B4FDAB1A13FF Q36838681-625C3CDA-D950-411C-AA13-715A50031319 Q37082698-E6D48E39-4686-485B-874D-3A1AA6F6AA5A Q37270524-B5799835-883C-47D5-A7BE-F25ECAF17997 Q37377861-ABBD9A7F-18D5-4BA6-B392-F8A033FB0C45 Q37701737-8DA6CFA6-C238-4B7C-B7FA-1738BB37B4F1 Q37864256-7A7CE739-DFDD-40B5-875E-804DB3F2ECC5 Q37933408-7E0FB58E-FC28-47FA-8191-C1BCEAD90D4F Q38253580-8A20102B-0E3F-4EB4-900E-4F996DD99AC7 Q38264360-C03AC74C-45EF-4879-8AC5-2583C41475AE Q38838461-FB6D9FDD-A18F-45EF-9D59-F22895668D8F Q41983958-5B251515-3F31-45AC-81F0-BAC1028587C7 Q42578569-EADE11D6-FE78-422E-8C18-0A8029712EF2 Q43279508-50D09156-54C5-47A7-81E3-018F04A61ECD Q48970248-47903BFF-8755-40B9-8A04-AACBA42BAD24 Q51378731-0B38881A-EA7D-4C04-8C08-94F43034BB65

P2860

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36715772

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@ast

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@en

type

label

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@ast

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@en

prefLabel

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@ast

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@en

P1433

Q36715772-3BA96FA2-F959-47DD-91A2-63DC5BD09503

P1476

Q36715772-38A01325-3FD8-4A44-B20E-15D5A1CEB42E

P2860

Q36715772-079F441B-DE37-441C-A0A0-606C0E6DD4BA

Q36715772-0879C2C6-53EA-47FA-BC05-1843918188A8

Q36715772-08B11F64-6C36-4A53-8ED1-7138179BE10F

Q36715772-0AABBBA1-84FD-4075-B38E-60FF15266E40

Q36715772-26834C95-7138-45E8-8F11-9AADE4963470

Q36715772-26FC667D-BEE0-42CD-8FA9-7D99331B227F

Q36715772-28B4FE0C-5241-439B-93B0-2734D5E85E2D

Q36715772-2ED5312F-ABB2-4A3E-86CB-14ECD1E6B5FB

Q36715772-2F225BB3-1CAC-4F21-85A8-1796B1BCDA00

Q36715772-34B77424-681C-41BB-80EE-404115A9D7A7

P304

Q36715772-3DE29058-7379-49CD-8B20-4E0F85E1F81B

P31

Q36715772-5BD27EDF-96DF-43AA-8E7A-961309EA3E0C

P356

Q36715772-F584BF1E-E26E-478A-A0A0-10BFB2E59EB3

P407

Q36715772-8B39F548-0FE9-404B-86FD-415F6452D127

P433

Q36715772-E6A5B841-9A2A-49F2-8DD7-20B88C9053D4

P478

Q36715772-86340B28-B8CF-4135-971C-5293DA4BA9F3

P50

Q36715772-8E08CA95-1634-40E7-8EC3-2ACC7385A4F1

P577

Q36715772-C7AD5657-DFEB-4CB6-8F87-CF18BE94CC9F

P698

Q36715772-1D3DF420-76A0-47A5-824B-4885F690C1E0

P921

Q36715772-253ECBA6-80B6-4BBE-AB8E-198C622938A9

P356

13543784.16.2.231

P1433

Expert Opinion on Investigational Drugs

P1476

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

@en

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

Incretins, insulin secretion and Type 2 diabetes mellitus.

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

New sources of pancreatic beta-cells.

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

P304

231-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.16.2.231

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17243943

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes